MedDataX Logo

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT ID: NCT04324164

Last Updated: 2025-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-24

Study Completion Date

2027-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638

Non Small Cell Lung Cancer Stage III Non-small-cell Lung Cancer EGFR Mutation-Related Tumors
UNKNOWN

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

NCT04207775

Locally Advanced or Metastatic NSCLC
COMPLETED

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141

Nonsmall Cell Lung Cancer
UNKNOWN

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217

Non-small Cell Lung Cancer Aquired Resistance EGFR TKIs
UNKNOWN

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781

Non-Small Cell Lung Cancer
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 Uncommon EGFR exon 19del

patients with uncommon EGFR exon 19del

Third-generation EGFR-TKI

Intervention Type DRUG

Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

Cohort 2 EGFR exon 19delins

patients with EGFR exon 19delins

Third-generation EGFR-TKI

Intervention Type DRUG

Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

Cohort 3 EGFR exon 18del

patients with EGFR exon 18del

EGFR-TKI

Intervention Type DRUG

All EGFR-TKI

Cohort 4 Common Uncommon Point Mutations

patients with common uncommon point mutations

EGFR-TKI

Intervention Type DRUG

All EGFR-TKI

Cohort 5 Rare Uncommon Point Mutations

patients with rare uncommon point mutations

EGFR-TKI

Intervention Type DRUG

All EGFR-TKI

Cohort 6 Compound Mutations Uncommon With Uncommon

patients with compound mutations uncommon with uncommon

EGFR-TKI

Intervention Type DRUG

All EGFR-TKI

Cohort 7 Compound Mutations Uncommon With Common

patients with compound mutations uncommon with common

EGFR-TKI

Intervention Type DRUG

All EGFR-TKI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Third-generation EGFR-TKI

Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

Intervention Type DRUG

EGFR-TKI

All EGFR-TKI

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology

* Uncommon EGFR Mutant Advanced NSCLC

Exclusion Criteria

* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hunan Province Tumor Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yongchang Zhang

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yongchang Zhang, MD

Role: PRINCIPAL_INVESTIGATOR

Hunan Cancer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yongchang Zhang

Changsha, Hunan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yongchang Zhang, MD

Role: CONTACT

[email protected]
+8613873123436 ext. 7+861383123436

Nong Yang, MD

Role: CONTACT

[email protected]
+8613055193557 ext. +8613873123436

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yongchang Zhang, MD

Role: primary

[email protected]
+8613873123436 ext. +8613873123436

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SONICS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
NCT01994057 RECRUITING
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505 RECRUITING PHASE2
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
NCT04206072 COMPLETED PHASE2/PHASE3
Evaluate EGFR Mutation Status and Impact Factors in North China
NCT02620657 COMPLETED
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
NCT06452433 NOT_YET_RECRUITING PHASE2
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
NCT07314216 NOT_YET_RECRUITING PHASE2
Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
NCT02250846 UNKNOWN PHASE2
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
NCT05997719 RECRUITING
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890 RECRUITING PHASE2
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
NCT06634667 NOT_YET_RECRUITING PHASE2
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084 ACTIVE_NOT_RECRUITING
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
NCT02961270 UNKNOWN PHASE2
A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC
NCT06422546 RECRUITING
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
NCT00874419 COMPLETED PHASE3
A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
NCT05934461 COMPLETED
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
NCT05284539 RECRUITING PHASE2
Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers
NCT06164574 COMPLETED
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
NCT06786208 NOT_YET_RECRUITING
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
NCT05514314 UNKNOWN PHASE2
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560 COMPLETED
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
NCT04785742 UNKNOWN PHASE2
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
NCT03123484 UNKNOWN PHASE2
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
NCT04830826 COMPLETED
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression
NCT03544814 COMPLETED PHASE2
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
NCT05546866 ACTIVE_NOT_RECRUITING PHASE2